The Latest Breaking News from BSX

Boston Scientific has outperformed the Dow recently, and analysts are strongly optimistic about the stock’s prospects.

Boston Scientific has significantly outperformed the broader market over the past year, and analysts maintain a very bullish view on its outlook.

Boston Scientific shows impressive growth in Q3 results, garnering bullish analyst support despite clinical trial setbacks.

With Boston Scientific gearing up to release its third-quarter earnings later this month, analysts expect double-digit earnings growth.

The healthcare industry is thriving, owing to the growing healthcare expenditure and aging population. Given the industry’s tailwinds, fundamentally sound healthcare stocks AbbVie (ABBV), Boston Scientific (BSX), and CVS Health (CVS) could be solid buys. Keep Reading….

Boston Scientific has outperformed the Nasdaq Composite over the past year, and analysts remain bullish on the stock’s prospects.

MedTech’s bright future is fueled by rapid tech advancements and increasing demand for medical devices, implants, and precision treatments, driven by an aging population and rising global disease rates. Given this backdrop, adding strong MedTech stocks like Boston Scientific (BSX), Stryker (SYK), and Abbott (ABT) to one’s portfolio could be…

Boston Scientific is expected to report its second-quarter earnings results this month, and Wall Street analysts expect a single-digit profit growth.

Boston Scientific recently reached an all-time high, outperforming the S&P 500 Index, with Wall Street analysts remaining bullish about the stock’s prospects.

Boston Scientific has significantly outperformed the broader market YTD, and Wall Street analysts are still bullish about the stock’s prospects.

Boston Scientific's first-quarter sales guidance is "impressive," an analyst said Wednesday as BSX stock hit a record high.